KODIAK SCIENCES INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
KODIAK SCIENCES INC. (KOD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- KODIAK SCIENCES INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.61M, a 25.78% decline year-over-year.
- KODIAK SCIENCES INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $12.15M, a 23.51% decline year-over-year.
- KODIAK SCIENCES INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $14.05M, a 5.16% decline year-over-year.
- KODIAK SCIENCES INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $15.64M, a 14.88% decline year-over-year.
- KODIAK SCIENCES INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $58.86M, a 2.24% decline from fiscal 2024.
- KODIAK SCIENCES INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $60.21M, a 32.01% decline from fiscal 2023.
- KODIAK SCIENCES INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $88.56M, a 16.48% decline from fiscal 2022.
- KODIAK SCIENCES INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $106.03M, a 72.73% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.61M 10-Q · filed 2026-08-13 | $23.76M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $12.15M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $58.86M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $14.05M 10-Q · filed 2025-11-13 | $29.69M derived: sum of 2 quarters · filed 2026-08-13 | $45.58M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $15.64M 10-Q · filed 2026-08-13 | $31.53M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $15.89M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $60.21M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $14.81M 10-Q · filed 2025-11-13 | $33.19M derived: sum of 2 quarters · filed 2025-11-13 | $51.59M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $18.38M 10-Q · filed 2025-11-13 | $36.78M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $18.41M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $88.56M 10-K · filed 2026-03-31 | |||
| 2023-09-30 | $13.95M 10-Q · filed 2024-11-14 | $39.75M derived: sum of 2 quarters · filed 2024-11-14 | $65.73M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $25.80M 10-Q · filed 2024-11-14 | $51.78M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $25.98M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $106.03M 10-K · filed 2025-03-27 | |||
| 2022-09-30 | $26.18M 10-Q · filed 2023-11-14 | $52.16M derived: sum of 2 quarters · filed 2023-11-14 | $80.25M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $25.98M 10-Q · filed 2023-11-14 | $54.07M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $28.09M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $61.38M 10-K · filed 2024-03-28 | |||
| 2021-09-30 | $12.38M 10-Q · filed 2022-11-09 | $23.46M derived: sum of 2 quarters · filed 2022-11-09 | $33.39M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $11.09M 10-Q · filed 2022-11-09 | $21.01M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $9.93M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $30.67M 10-K · filed 2023-03-28 | |||
| 2020-09-30 | $8.24M 10-Q · filed 2021-11-09 | $15.13M derived: sum of 2 quarters · filed 2021-11-09 | $21.21M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $6.89M 10-Q · filed 2021-11-09 | $12.97M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $6.08M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $6.11M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $1.77M 10-Q · filed 2020-11-09 | $3.02M derived: sum of 2 quarters · filed 2020-11-09 | $4.17M derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $1.24M 10-Q · filed 2020-11-09 | $2.40M derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $1.16M 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $2.76M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $800.00K 10-Q · filed 2019-11-12 | $1.55M derived: sum of 2 quarters · filed 2019-11-12 | $1.64M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $748.00K 10-Q · filed 2019-11-12 | $840.00K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $92.00K 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $275.00K 10-K · filed 2020-03-16 | |||
| 2016-12-31 | $272.00K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |